• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Nexalin Technology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    5/5/25 6:03:32 AM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $NXL alert in real time by email
    false 0001527352 0001527352 2025-05-05 2025-05-05 0001527352 nxl:CommonStockParValue0.001PerShareMember 2025-05-05 2025-05-05 0001527352 nxl:WarrantsEachExercisableForOneShareOfCommonStockMember 2025-05-05 2025-05-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): May 5, 2025

     

    NEXALIN TECHNOLOGY, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41507   27-5566468
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)

     

    1776 Yorktown, Suite 550

    Houston, TX 77056

    Registrant’s telephone number, including area code: (832) 260-0222

     

     

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.001 per share   NXL   The Nasdaq Stock Market LLC
             
    Warrants, each exercisable for one share of Common Stock   NXLIW   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

     

     

     

       

     

     

    Item 1.01Entry into a Material Definitive Agreement.

     

    On April 29, 2025, Nexalin Technology, Inc., a Delaware corporation headquartered in Houston, Texas (the “Company”) established an “at-the-market” offering (the “ATM Program”) through which the Company may sell, from time to time through Maxim Group LLC, as exclusive sales agent (the “Agent”), shares of the Company’s common stock, par value $0.001 per share (the “Shares”).

     

    On May 5, 2025, in connection with the Company’s effective shelf registration statement on Form S-3 (File No. 333-286711) (the “Registration Statement”), the Company entered into Amendment No. 1 (the “Amendment”) to the equity distribution agreement, dated April 29, 2025 (the “Equity Distribution Agreement”) with the Agent. The Amendment was entered into by and between the Company and the Agent in order to reduce the maximum amount of shares of the Company’s common stock that may be issued and sold through the Agent, from an aggregate offering price from $9,777,825 to an aggregate offering price of up to $3,100,000. As of May 5, 2025, up to approximately $3,100,000 million in aggregate amount of the Shares remain available for sale under the ATM Program.

     

    Further details regarding the Equity Distribution Agreement, as amended by the Amendment, and the ATM Program are set forth in the Company’s prospectus supplement, dated May 5, 2025 (the “New ATM Prospectus Supplement”) and the accompanying prospectus, dated April 29, 2025 (together with the New ATM Prospectus Supplement, the “Prospectus”), filed by the Company with the Securities and Exchange Commission.

     

    The foregoing description of the Amendment is not complete and is qualified in its entirety by reference to the full text of the Amendment, a copy of which is attached hereto as Exhibit 10.1 and is incorporated herein by reference. A copy of the opinion of Warshaw Burstein relating to the legality of the issuance and sale of the Shares pursuant to the Prospectus is attached as Exhibit 5.1 hereto.

     

    The Shares, if any, will be issued pursuant to the Registration Statement dated April 29, 2025, and the New ATM Prospectus Supplement dated May 5, 2025, and the Prospectus, as supplemented from time to time.

     

    This Current Report on Form 8-K shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

     

    Item 9.01.Financial Statements and Exhibits.

     

    (d)Exhibits.

     

    Exhibit  

    Description

    5.1   Opinion of Warshaw Burstein, LLP
    10.1   Amendment No. 1 to Equity Distribution Agreement

     

     1 

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report on form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

     

      NEXALIN TECHNOLOGY, INC.
       
      By: /s/ Mark White
        Mark White
        Chief Executive Officer

     

    Dated: May 5, 2025

     

     2 
    Get the next $NXL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NXL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NXL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Sr. VP - Quality, Regulatory Shelton Carolyn Hamby bought $13,200 worth of shares (6,000 units at $2.20) (SEC Form 4)

      4 - Nexalin Technology, Inc. (0001527352) (Issuer)

      3/13/25 4:52:26 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Medical Officer Owens David bought $3,100 worth of shares (1,000 units at $3.10), increasing direct ownership by 0.65% to 155,793 units (SEC Form 4)

      4 - Nexalin Technology, Inc. (0001527352) (Issuer)

      2/5/25 3:17:26 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Medical Officer Owens David bought $2,980 worth of shares (1,000 units at $2.98), increasing direct ownership by 0.65% to 154,793 units (SEC Form 4)

      4 - Nexalin Technology, Inc. (0001527352) (Issuer)

      2/4/25 5:05:25 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NXL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Sr. VP - Quality, Regulatory Shelton Carolyn Hamby bought $13,200 worth of shares (6,000 units at $2.20) (SEC Form 4)

      4 - Nexalin Technology, Inc. (0001527352) (Issuer)

      3/13/25 4:52:26 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by President and CEO White Mark

      4 - Nexalin Technology, Inc. (0001527352) (Issuer)

      2/27/25 4:34:13 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Owens David

      4 - Nexalin Technology, Inc. (0001527352) (Issuer)

      2/27/25 4:33:38 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NXL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on June 3

      HOUSTON, TX, May 28, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (NASDAQ:NXL, NXLIW)) is pleased to invite investors to a webinar on June 3, 2025, at 4:15 p.m. ET. Attendees will gain an inside look at Nexalin's game-changing approach to mental healthcare through its proprietary, non-invasive Deep Intracranial Frequency Stimulation (DIFS™) technology. CEO Mark White will detail the Company's growing body of clinical evidence, including collaborations with leading institutions like UC San Diego, and share updates on the Gen-3 HALO™ Clarity headset and Virtual Clinic model—designed for scalable, at-home treatment. With regulatory approvals secured interna

      5/28/25 10:00:00 AM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer's Program Amid Encouraging Data

      HOUSTON, TX, May 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin") the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the reconstitution of its Scientific Advisory Board (SAB) with the appointment of three renowned experts in neurology, neuroimaging, and neurodegenerative diseases. This move reflects Nexalin's strategic prioritization of Alzheimer's disease within its broader clinical development pipeline, supported by promising published data and internal data from studies involving its proprietary DIFS™ technology. Joining the SAB are Dr. Mingxiong Huang, Dr. David Owens, and Dr. Abe Scheer, e

      5/13/25 8:30:00 AM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering

      HOUSTON, May 06, 2025 (GLOBE NEWSWIRE) --  Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the closing of its previously announced underwritten public offering of 3,850,000 shares of its common stock at a public offering price of $1.30 per share. The gross proceeds from the offering to Nexalin were approximately $5.0 million, before deducting underwriting discounts and commissions and other offering expenses. Maxim Group LLC acted as sole book-running manager for the offering. The public offering was made pursuant to an effective shelf registration statement on Form S-3

      5/6/25 2:40:23 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NXL
    SEC Filings

    See more
    • SEC Form 10-Q filed by Nexalin Technology Inc.

      10-Q - Nexalin Technology, Inc. (0001527352) (Filer)

      5/13/25 3:31:04 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nexalin Technology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - Nexalin Technology, Inc. (0001527352) (Filer)

      5/6/25 12:39:21 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 424B4 filed by Nexalin Technology Inc.

      424B4 - Nexalin Technology, Inc. (0001527352) (Filer)

      5/6/25 11:44:26 AM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NXL
    Leadership Updates

    Live Leadership Updates

    See more
    • Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer's Program Amid Encouraging Data

      HOUSTON, TX, May 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin") the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the reconstitution of its Scientific Advisory Board (SAB) with the appointment of three renowned experts in neurology, neuroimaging, and neurodegenerative diseases. This move reflects Nexalin's strategic prioritization of Alzheimer's disease within its broader clinical development pipeline, supported by promising published data and internal data from studies involving its proprietary DIFS™ technology. Joining the SAB are Dr. Mingxiong Huang, Dr. David Owens, and Dr. Abe Scheer, e

      5/13/25 8:30:00 AM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board

      HOUSTON, TX, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin") the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, is honored to announce that General Wesley K. Clark (Ret.), former NATO Supreme Allied Commander Europe, has joined its Military & Government Advisory Board. General Clark will collaborate with esteemed members David F. Lasseter, former Deputy Assistant Secretary of Defense for Policy, and William A. Hudson, Jr., former Acting General Counsel to the Department of Veterans Affairs, to advance Nexalin's innovative neurostimulation solutions within U.S. military and government sectors. The Company'

      2/26/25 8:30:00 AM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs

      HOUSTON, TX, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW))) (the "Company" or "Nexalin") announces the appointment of Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs. With more than 30 years of experience in the medical device industry, Shelton brings a wealth of knowledge in regulatory compliance, quality assurance, and clinical development. In her role, she will oversee all clinical studies, quality systems, and regulatory submissions, ensuring Nexalin's commitment to innovation, safety, and excellence as the Company prepares to pursue global regulatory clearances and future FDA Breakthrough Device designations for its

      10/14/24 8:30:00 AM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NXL
    Financials

    Live finance-specific insights

    See more
    • LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / November 1, 2024 / RedChip Companies will air interviews with LOBO EV Technologies Ltd. (NASDAQ:LOBO) and Nexalin Technology, Inc. (NASDAQ:NXL) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, November 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:LOBO EV: https://www.redchip.com/assets/access/lobo_accessNexalin: https://www.redchip.com/assets/access/nxl_accessIn an exclusive interview, Harry D. Schulman, Independent Director of LOBO EV Technologies, appears on the RedChip Small Stocks Big Money™ show on Bloomberg T

      11/1/24 9:00:00 AM ET
      $LOBO
      $NXL
      Motor Vehicles
      Consumer Discretionary
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / October 25, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (NASDAQ:NXL) and Calidi Biotherapeutics, Inc. (NYSE:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 26, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Nexalin: https://www.redchip.com/assets/access/nxl_accessCalidi: https://www.redchip.com/assets/access/cldi_accessIn an exclusive interview, Mark White, CEO of Nexalin Technology, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate

      10/25/24 9:00:00 AM ET
      $CLDI
      $NXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Nexalin Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / July 26, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (NASDAQ:NXL) and LOBO EV Technologies Ltd. (NASDAQ:LOBO) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 27, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Nexalin: https://www.redchip.com/assets/access/nxl_accessLOBO EV: https://www.redchip.com/assets/access/lobo_accessMark White, CEO of Nexalin, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate update. Nexalin stands at the forefront of th

      7/26/24 9:55:00 AM ET
      $LOBO
      $NXL
      Motor Vehicles
      Consumer Discretionary
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care